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The cDNA for human ferrochelatase, the enzyme 
that is defective in the rare genetic disease erythro-
poietic protoporphyria (EPP), was tested for its ability 
to allow the expression of ferrochelatase in mamma-
lian cells. The cDNA was ligated to the plasmid 
expression vectors pCD and pED6 and transfected 
into COS-l and CHO-DUKX cells, respectively. In 
each case, ferrochelatase activity increased. The 
cDNA was also ligated into the retroviral vector 
pLXSN, and virus-packaging cells were prodnced. 
Supernatants from these cells were used to infect 
F errochelatase (EC 4.99.1.1), the enzyme that catalyzes the insertion of iron into protoporphyrin to form heme, is defective in the rare genetic disease erythropoietic protoporphyria (EPP). Tlus defect causes the accumu-lation of protoporphyrin, which gives rise to the pho-
tosensitivity characteristic of this disease [1] . The enzyme has been 
purified from rodent [2], beef [3,4], chkken [5], and human [6] 
tissues, and its cDNA has been cloned from a mouse erythroleu-
kemia cell cDNA library [7] and from a human placenta cDNA 
library [8). Introduction of the cDNA for murine ferrochelatase 
into COS cells lIin the plasmid vector pCD resulted in an increase 
in the cells' ferrochelatase activity [7] . Although human ferro che-
latase cDNA has been expressed in Esche/icllin coli [9], the effect on 
ferrochelatas e activity of introducing the gene for human ferroche-
latase into mammalian cells has not been studied to date . We report 
here that the addition of the human ferrochelatase eDNA to 
SV40-transformed African green monkey kidney (COS-1) cells, to 
Chinese hamster ovary (CHO) cells, and to fibroblasts from a 
patient with EPP results in an increase in ferro chelatase enzym e 
activity in each of these cell lines. 
MATER.lALS Af\!D METHODS 
Biologic Material T he eDNA for human ferrochclatase (,\MF2.1: 1.6 
kilobase pain), ligated into the EcoR.l sitc of the plasmid vector pUC18, was 
supplied by Dr. Shigeru Taketani. Fibroblasts fi'om a geneti ca Uy normal 
individual (accession number GM05659) and from a patient with EPP 
(accession number GM05008A ; found by Brenner ef al (1 0) to have a 
phenylalanine-to-serine substitution at amino acid position 417 of ferroche-
latase in the carboxy-terminal end of the protein) were obtained from the 
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fibroblasts in vitro from a patient with EPP. We found 
that the infected cells containing the ferrochelatase 
cDNA had enzyme levels in the range of normal 
fibroblasts and that they did not accumulate proto-
porphyrin when grown in the presence of o-amino-
levulinic acid. We conclude that introducing the 
eDNA for normal ferrochelatase into fibroblasts from 
an EPP patient restores ferrochelatase enzyme activ-
ity to the normal range. These experiments suggest 
potential for genetic therapy in EPP. Key Ivol,ds: lyasesl 
gene expression, ] [tlllest Deyttlatol 104:497-499, 1995 
National Institute ofGener,,1 Medical Scienccs Human Genetic Murant Cell 
Repository (Camden, NJ). The DK1, DH5a, and HBlOt strains of 
Escllel'ichia coli were from the Channing Laboratory collection. T he plasmid 
vector pCD was provided by Dr. Mashihito Negishi, and pED6 by Dr. 
Randall Kaufillan. T he retroviral vector pLXSN and the virus packaging 
cell lines PA317 and PE501 were providcd by Dr. A. Dusry Miller. 
Insertion of Fcrrochelatase cDNA into Vectors T he pUC vector 
containing human ferrochelatase cDNA was digested with EcoR1 (New 
England Biolabs, Bcverly, MA): the cDNA insert and plasmid were 
separated by elec trophoresis on low-melting-point agarose . Vectors were 
linearizcd by digestion with EcoR.1, the ends were treated with alka.line 
phosphatasc, and the ferrochelatase cDNA was ligated into the vectors using 
standard techniques [11 ,12). The orientation of the ferroche latase cDNA in 
each vector was verificd by digestion with BalllHl . Stocks of plasm ids with 
and without the fcrrochelatase cDNA wcre maintained in the fo llowing 
E. coli strains: pUC in DK1. pCD and pED6 in HBl01, and pLXSN in 
DH5a. The bacterial cells cont<lining the vectors wcre frozen in 20% 
glycerol 311d stored at - 20°C. 
Tissue Culture Techniques A.I1 cell s were grown on Dulbecco 's min-
imal essential medium supplemented with a final conccntration of 2 mM 
glutamine, 100 U penicillin, 100 /-Lg streptomycin, and 0.25 /-Lg Fungizone 
(GIDCO BRL Life Tecl1J1ologies. Gaithersburg, MD) in an atmosphere of 
5% CO2 , COS-1 and C HO cell s were supplemented with 10% fcta l bovine 
serum and 1 gil glucose; PA317 and PE50l cell s werc supplemented with 
10% fetal bovine serum and 4.5 gil glucose. T he human fibroblast strains 
were supplemented with 20% fetal bovine serum, 4.5 gi l glucose. 311d 
minimal essential medium-nonessential amino acids solution (GIDCO BRL 
Life TcclulOlogies) . For studies of porphyrin accumulation , 25 /-LM iron as 
FeSO. and 100 p.M 8-aminolevulinic acid were added to the culture 
medium of the three human fibrobla st cell lines for 24 h before harvesting. 
as described previously [13 ,14). 
COS-1 cell s were transfected with pCD containing the ferrochelatase 
cDNA by the dicthylaminoethyl / dextran method ill)· C HO-DUKX cells 
were transfected with ferrochelatase cDNA in pED6 (15) by lipofection 
with Lipofectin (GIBCO BRL Life Techno logies). according to the m3nu-
f.1 cturer's protocol. Stably transformed CHO-DUKX cells were selectcd. 
0022-202X/95/S09 .50 ' SSDI0022-202X(95)00003-4 ' Copyright © 1995 by T he Sociery for Investigative Dennatology, Inc. 
497 
498 MATHEWS-ROTH ET AL 
and expression levels were amplified as described previously [16]. Perma-
nent virus-producing cells were made by the technique of Miller and 
Rosman [17], and the human fibrob last strains were infected with virus-
containing supernatants from these ce lls by the polybrene method [17] . 
Stably infected cell lines were se lected for geneticin (G-418) resistance and 
were subcul tured and main tained in the presence of the antibiotic. 
Assay for Ferrochelatase Activity Two or three plates of cells were 
used for each determination of enzyme activity. T he ce ll s were rinsed, 
scraped off the d ishes, and rinsed again in a buffer consisting of 20 mM 
Tris-HCI (pH 8.2), 1 mM ditluothre itol , and 10 ILg/ml phcnylmethylsul-
fony l Auoride. Cells were then homogcnized in a Ten Broeck tissue grinder 
and assayed for ferrochelatase activity accord ing to the method of Da iley 
and Fleming [4], with de uteroporphyrin as a substrate. An aliquot of the cell 
extract used fo r the ferrochclatase assay was analyzed for total protein 
content using the BCA protein assay reagent (Pierce, Rockland, IL). 
Porphyrin Extraction After 24 h of incubation in the presence of 
cS-anunolevuIinic acid and iron, fibroblasts we re scraped from the culture 
dish and washed two times with saline; the pelleted ce ll s were extractcd 
with 0.5 ml of 1 N perchloric acid :methanol (1:1 vol/vo l) for 5 min. After 
tlus incubation, the ulbes were cen trifuged and the supernatan t was 
completely removed without di sturbing the pellet of precipitated cell ular 
materia l [13,14] . Porphyrin accum ulatio·n was determined by measuring the 
Auorescence of the supernatant with a T urner Fi.lter Fluorometer fittcd with 
a 405-nm narrow-pass primary fi lter and a 600-nm sha rp-cut secondary 
filter. Protein was measured by digestion of the p recipitate of ce llular 
materi al in 0 .5 N NaOH for 1 h at 60°C and ana lysis for protein using the 
BC A reagent. An aliquot of the digest was diluted to 0.1 N NaOH, and the 
manufacturer's cnhan ccd protocol for prote in assay with BCA reagent was 
used. 
RESULTS AN D DISCUSSION 
Ferrochelatase enzyme activity was determined in the three ce ll 
lines studied (Table I). In the experim ent with COS cells, cells 
transfected with pCD containing no insert were used as the control. 
Preliminary experitnelits showed that ferrochelatase activity in cells 
receiving either no plasmid or plasm id without ferrochela tase 
cDNA did not differ significantly (p < 0.7). T hus, in the experi-
ments with CHO cells and human fibroblasts, we used ceIJ s with no 
plasmids as controls. Taketani eI nl [7] also fo und no difference in 
ferroc helatase activity between COS cells witho ut plasm ids and 
COS cells with plasmid containing no insert. 
As is shown in Table I, transfection of COS cells w ith pCD-
ferrochelatase cDN A produced a fivefold in crease in activity, a 
result consistent with the fivefold in crease reported by Taketal1.i e/ 
nl for COS cells transfected with pCD contain ing the cDN A for 
mouse ferrochelatase [7]. T he increase in activity in pED- ferroche-
latase-transfected CHO cells was about three times that in non-
transfected cell s. Th us, both ce ll lines transfected with the hum an 
ferro chelatase cDNA had increased ferrochelatase enzyme activity. 
As a result of our findings in COS and CHO cells, we thought it 
Table I. Ferrochelatase Activity in Extracts of Control 
Cells and Cells Receiving the Human Ferroch elatase 
cDNA 
nM Hcme/ l11g Protein/ h 
Number of 
Cell s Mean :': SEM Experiments Range 
COS-l cell s + pCD 7.4 :': 2.93 2 3.26-11.55 
COS-l cells + pCD- 47 .07 :': 23.61 2 13.67-80.96 
fcrrochclatase 
CHO-DVI<X cells not 10.88 :': 1.64 3 8.45-14 .87 
transfected 
C HO-DVI<X cells + pED- 30.11 :': 2.72 5 22.77-39.47 
ferrochelatase 
NOml"l fibroblasts not 26.99 :!: 4.03 3 17.95-34.97 
infected 
EPP fibroblasts not infected 10.58 :': 2.87 5 3.89-19.7 
EPP fibrob lasts + pLXSN- 87 .37 :': 28 .14 5 28.95-191.14 
ferrochelatase 
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of interest to attempt similar studies using fibroblasts from patients 
with EPP. Geneticin-resistant clones were isolated after infecting 
the EPP patient fibroblasts (GMOS008A) with the retroviral vector 
pLXSN con taining the human ferroche latase cDN A. As can also be 
seen fi·om Table I, infection of the fibroblasts res tored enzym e 
ac tivity to the norm al range. Table II shows tha t the added 
ferrochelatase cD NA also prevented most of the large accumulation 
of protoporphyrin in fibroblasts from the EPP patient that occurred 
when the cells were cul tured in the presence of o-aminolevulinic 
acid for 24 h. T he increased ferrochelatase activity in th e EPP 
fibroblasts was n o t diminished in seven successive passages over a 
period of2 months. The infected EPP fibroblasts were grown in the 
presence of Geneticin in all passages. 
Our results extend the fll1dings of Taketani ct nl [7] on the 
expression of m o use ferrochelatase by showing that transfected 
human ferroc helatase can also allow the expression of active 
ferrochelatase in animal cell s and, more important, allow its 
expression in fibrob lasts from an EPP patient. T h e added ferroche-
latase cDNA restored en zym e activity leve ls in these cell s to the 
normal range, as measured in cell extracts . It also prevented the 
accumulation of excess protoporphyrin in the intact EPP fibroblasts, 
although not quite with the efficiency of the norma l fibroblasts. 
Our findings suggest that genetic therapy for EPP m ay be feasible. 
H eme is present in all cell s. Because heme is a component not 
only of hemoglobin , bu t also of myoglobin and all cytochro mes, 
including P-4S0, and is absolutely n ecessa ry for the transport and 
storage of oxygen , all cel.l s must have the capacity to synthesize it. 
Indeed, fe rrochelatase activity ha s been found in all human cell s 
surveyed . Although ferrochelatase activity in EPP patients can 
range from 5% to 50% of normal, very rarely do these patients 
develop an anemia serious enough to necessitate treatm en t [1]. T he 
remaining ferrochelatase activity also appears to be suffi cient to 
provide hem oproteins in aLlnonerythroid cells. About 85% of heme 
is synthesized by erythroid cells [1] ; thus, th e excess protoporphyrin 
accumul atin g in the se rum , skin , and live r and excreted in the stool 
in EPP comes fro m the erythron, not the liver or o th er organ s and 
tissues. In fact, the porphyrin tha t accumulates in the liver, causing 
le thal liver disease in rare individuals, has been shown to come from 
the erythron and not the liver itself [1 8]. T hu s, if gen etic therapy 
were conside red for EPP, the appropriate target cells for this 
therapy would be bone marrow stem cells. 
Although relatively successful treatments for EPP exis t [1 9,20], 
they are not effective in all patients, and thu s the possibility of 
genetic therapy for th.is condition is worth considering. However, 
at this time, genetic therapy for any hematologic disease remains 
only a theore tical possibility because of many teclmical problems. 
For example, altho ugh some advances have been made [21], 
hematopoietic stem cell s are not easily isolated. T here are also 
questions about the abili ty of retrovinl l vectors to infect stem cells 
e ffi ciently and cause permanent genetic change, as well as concerns 
about long-term safe ty. In additi on, investigators will have to show 
for each diffe l·ent ferrochelatase mutation that addin g the normal 
ferroch elatase cDN A w ill indeed iJlcrease the enzyme activ ity. 
O nce these many techni cal issues are reso lved, resultin g in safe and 
effective m ethods of gene delivery, genetic therapy co uld be an 
option for those EPP patients with severe photosensitivity that does 
Table II. Protoporphyrin Accumulation in Normal 
Fibroblasts, EPP F ibroblasts, and EPP Fibroblasts 




EPP + pLXSN-fcrrochclatase 
fI Average of dupliciltc experiments. 
I'M Protoporphyrin / mg Protein" 
Mea n :!: SEM 
37.7 :': 2.4 
486.8 :': 50.2 
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not respond to presently available methods of photoprotection or 
for patients with extremely high levels of protoporphyrin that put 
them at risk for the development of potentially lethal protoporphy-
rill-induced tiver damage . 
T llis stlld), ",as sIIpported by gra llts to M.M-R. ji'Ol ll til e A lll ericall POIpll )'ria 
POI llldalioll alld T il e Brishalll Nledical cro llP. RJ. I~/. is sIIpported by a s rallt jimll 
tile A lll ericall H eart FCI/Illdatioll . I¥e tllallk D,>·. Siligel'll Taketalli, J\1as ll illito 
Negis /,;, alld A. D llsl), Millerj;,r Ille c~!fis of til e IJectors alld cells IIsed ill tllis stlld),. 
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